Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of belimumab in adults with systemic sclerosis-associated interstitial lung disease
MOH_2026-02-03_015634Phase 3Recruiting
- Sponsor
- GSK
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of belimumab in pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD), sponsored by GSK. Started Jan 2026; status: recruiting.
02
Drugs
belimumab
03
Conditions
pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)
Beyond the preview
Go deeper on MOH_2026-02-03_015634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-02-03_015634.